



Oliver Dorigo, M.D., Ph.D.

Associate Professor of Obstetrics and Gynecology (Oncology) at the Stanford University Medical Center

Obstetrics & Gynecology - Gynecologic Oncology

CLINICAL OFFICES

- **Gynecology Clinic**

900 Blake Wilbur Dr

Palo Alto, CA 94304

Tel (650) 498-6004

Fax (650) 498-7237

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Helen Wong - Administrative Assistant

Email hswong@stanford.edu

Tel (650) 724-0456

Bio

CLINICAL FOCUS

- Cancer > Gynecologic Cancer
- Gynecologic Oncology

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Obstetrics & Gynecology - Gynecologic Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Director, Stanford Gynecologic Oncology Fellowship, (2016- present)
- Director, Stanford Clinical Research Group for Gynecologic Cancer Trials, (2014- present)
- Director, Stanford Gynecologic Oncology Clinical Care Program, (2013- present)
- Director, Mary Lake Polan Gynecologic Oncology Research Laboratory, (2013- present)
- Director, Stanford Obstetrics and Gynecology, Division of Gynecologic Oncology, (2013- present)

HONORS AND AWARDS

- American Association of Cancer Research Outstanding Poster Award, Toronto, Canada, American Association of Cancer Research, Toronto, Canada (1995)
- Outstanding Podium Presentation Award, National Gynecologic Oncology Fellow's Forum (2004)
- Teaching Award, National Council on Resident Education in Obstetrics and Gynecology (2007)
- STOP Cancer Career Development Award, STOP Cancer (2008)
- OB/GYN Resident Teaching Award, University of California, Los Angeles (2008)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Society of Pelvic Surgeons (2016 - present)
- Member, American Association of Cancer Research (1996 - present)

- Member, American Gynecological and Obstetrical Society (2016 - present)
- Member, Society of Gynecologic Investigations (2000 - present)
- Member, American Society of Gene Therapy (2000 - present)
- Member, Society of Gynecologic Oncology (2005 - present)
- Member, Gynecologic Oncology Group (2005 - present)

PROFESSIONAL EDUCATION

- Fellowship: UCLA Medical Center Obstetrics and Gynecology Fellowships (2005) CA
- Residency: UCLA Medical Center Obstetrics and Gynecology Residency (1999) CA
- Medical Education: University of Heidelberg (1989) Germany
- Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (2008)
- Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (2006)
- PhD, University of California, Los Angeles , Molecular Biology (2003)
- Residency: Ludwig Maximillians University (1992) Germany

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Health and Recovery Program in Increasing Physical Activity Level in Stage IA-III A Endometrial Cancer Survivors, Recruiting
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer, Recruiting
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer, Not Recruiting
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens, Not Recruiting
- Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191), Not Recruiting
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients, Not Recruiting
- CT Antigen TCR-redirected T Cells for Ovarian Cancer., Not Recruiting
- Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment, Not Recruiting
- Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN, Not Recruiting
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy., Not Recruiting
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer, Not Recruiting
- Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer, Not Recruiting
- Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer, Not Recruiting
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules, Not Recruiting
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer, Not Recruiting
- Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting

Publications

PUBLICATIONS

- **Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis** *CANCER RESEARCH*
Natarajan, S., Foreman, K. M., Soriano, M., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., Heilshorn, S. C., Sinha, S., Fuh, et al
2019; 79 (9): 2271–84
- **The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., Yu, J., Woods, E. C., Kramer, J. R., Westerlind, U., Dorigo, O., Bertozzi, C. R.
2019; 116 (15): 7278–87
- **Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.** *Cancer research*
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., Heilshorn, S. C., Sinha, S., Fuh, et al
2019
- **Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx.** *Developmental cell*
Möckl, L., Pedram, K., Roy, A. R., Krishnan, V., Gustavsson, A. K., Dorigo, O., Bertozzi, C. R., Moerner, W. E.
2019
- **The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.** *Proceedings of the National Academy of Sciences of the United States of America*
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., Yu, J., Woods, E. C., Kramer, J. R., Westerlind, U., Dorigo, O., Bertozzi, C. R.
2019
- **Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Koh, W., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Clark, R., Cohn, D., Crispens, M. A., Damast, S., Dorigo, et al
2019; 17 (1): 64–84
- **Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States.** *Journal of minimally invasive gynecology*
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., Karam, A.
2019
- **Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Levinson, K., Dorigo, O., Rubin, K., Moore, K.
2019; e126–e140
- **Cell-based immunotherapy in gynecologic malignancies.** *Current opinion in obstetrics & gynecology*
Schaar, B., Krishnan, V., Tallapragada, S., Chanana, A., Dorigo, O.
2018
- **Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis.**
Foreman, K., Fuh, K., Soriano, M., Dorigo, O., Krishnan, V., Shehade, H., Natarajan, S., Sinha, S., Krieg, A., Rankin, E.
AMER ASSOC CANCER RESEARCH.2018: 57
- **Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Koh, W., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H., Chu, C., Cohn, D., Crispens, M., Damast, S., Dorigo, O., Eifel, et al
2018; 16 (2): 170–99
- **Cell-based immunotherapy in gynecologic malignancies.** *Current opinion in obstetrics & gynecology*
Schaar, B., Krishnan, V., Tallapragada, S., Dorigo, O.
2018; 30 (1): 23–30
- **Tumor associated macrophages in gynecologic cancers.** *Gynecologic oncology*

Krishnan, V., Schaar, B., Tallapragada, S., Dorigo, O.
2018

- **Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials** *ONCOTARGET*
MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A., Fleming, G. F., Mutch, D. G., Nephew, K. P., Wentzensen, N., Goodfellow, P. J., Dorigo, O., Nijman, et al
2017; 8 (48): 84579-94
- **Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.** *Molecular imaging and biology*
He, H., Chiu, A. C., Kanada, M., Schaar, B. T., Krishnan, V., Contag, C. H., Dorigo, O.
2017
- **Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Koh, W., Greer, B. E., Abu-Rustum, N. R., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Cohn, D., Crispens, M. A., Dizon, D. S., Dorigo, O., Eifel, P. J., Fisher, et al
2017; 15 (1): 92-120
- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*
Porter, J. B.
2017; 13 (8): e673-e682
- **Women's cancer: Advancing molecular and immunotherapy** *CURRENT PROBLEMS IN CANCER*
Dorigo, O.
2017; 41 (1): 7
- **Immunotherapy in ovarian cancer** *CURRENT PROBLEMS IN CANCER*
Krishnan, V., Berek, J. S., Dorigo, O.
2017; 41 (1): 48-63
- **Immunotherapy in ovarian cancer.** *Current problems in cancer*
Krishnan, V., Berek, J. S., Dorigo, O.
2016
- **Ovarian Cancer, Version 1.2016** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., Gershenson, D. M., Gray, H. J., Hakam, et al
2016; 14 (9): 1134-1163
- **Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network*
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., Gershenson, D. M., Gray, H. J., Hakam, et al
2016; 14 (9): 1134-1163
- **Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma.** *Gynecologic oncology reports*
Nosratan-Baskovic, M., Tan, B., Folkins, A., Chisholm, K. M., Dorigo, O.
2016; 17: 38-41
- **Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer** *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*
Minamimoto, R., Karam, A., Jamali, M., Barkhodari, A., Gambhir, S. S., Dorigo, O., Iagaru, A.
2016; 43 (6): 1047-1055
- **Screening cell mechanotype by parallel microfiltration** *SCIENTIFIC REPORTS*
Qi, D., Gill, N. K., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., Taylor-Harding, B., Wiedemeyer, W. R., Rowat, A. C.
2015; 5
- **Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer** *CANCER RESEARCH*
Moughon, D. L., He, H., Schokrpur, S., Jiang, Z. K., Yaqoob, M., David, J., Lin, C., Iruela-Arispe, M. L., Dorigo, O., Wu, L.

2015; 75 (22): 4742-4752

- **Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dizon, D. S., Dorigo, O., Eifel, P. J., Fisher, et al
2015; 13 (11): 1321-1331
- **Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta** *OBSTETRICS AND GYNECOLOGY*
Judy, A. E., Lyell, D. J., Druzin, M. L., Dorigo, O.
2015; 126 (5): 1016-1018
- **Single cell analysis of ascites macrophages in ovarian cancer**
He, H., Yu, F., Quake, S. R., Dorigo, O.
AMER ASSOC CANCER RESEARCH.2015
- **Parallel microfiltration (PMF): A novel method to screen cell mechanotype**
Wiedemeyer, W., Qi, D., Gi, N., Santiskulvong, C., Dorigo, O., Rao, J., Taylor-Harding, B., Rowat, A. C.
AMER ASSOC CANCER RESEARCH.2015
- **Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identify targeted therapy options.**
Elvin, J., Bailey, M., Carneiro, B. A., Ali, S., Vergilio, J., Palma, N., Chmielecki, J., Frampton, G., Lipson, D., Stephens, P., Miller, V. A., Johnson, M., Giles, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Cervical cancer, version 2.2015.** *Journal of the National Comprehensive Cancer Network*
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dorigo, O., Eifel, P. J., Fisher, C. M., Frederick, et al
2015; 13 (4): 395-404
- **Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dorigo, O., Eifel, P. J., Fisher, C. M., Frederick, et al
2015; 13 (4): 395-404
- **Immunotherapeutic approaches to ovarian cancer treatment.** *Journal for immunotherapy of cancer*
Chester, C., Dorigo, O., Berek, J. S., Kohrt, H.
2015; 3: 7-?
- **M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer**
Moughon, D., He, H., Schokrpur, S., Jiang, Z., Yaqoob, M., David, J., Iruela-Arispe, L., Dorigo, O., Wu, L.
AMER ASSOC CANCER RESEARCH.2015
- **Screening cell mechanotype by parallel microfiltration.** *Scientific reports*
Qi, D., Kaur Gill, N., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., Taylor-Harding, B., Ruprecht Wiedemeyer, W., Rowat, A. C.
2015; 5: 17595-?
- **The role of tumor associated macrophages in ovarian cancer**
He, H., Moughon, D. L., Hillerup, C., ElMasri, W., Wu, L., Dorigo, O.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2014: 385
- **Mutational analysis of serous ovarian cancer using Ion Torrent sequencing**
Masghati, S., Dorigo, O., Santiskulvong, C.
AMER ASSOC CANCER RESEARCH.2014
- **Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease.** *British journal of dermatology*
Karam, A., Dorigo, O.
2014; 170 (3): 661-671
- **Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.** *Obstetrics and gynecology*
Masghati, S., Nosratian, M., Dorigo, O.
2014; 123 (2): 433-435

- **The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells** *INTEGRATIVE BIOLOGY*
Sharma, S., Santiskulvong, C., Rao, J., Gimzewski, J. K., Dorigo, O.
2014; 6 (6): 611-617
- **MMPs in Ovarian Cancer as Therapeutic Targets** *ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY*
Karam, A., Dorigo, O.
2012; 12 (7): 764-772
- **Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm** *HUMAN PATHOLOGY*
Stoll, L. M., Parvataneni, R., Johnson, M. W., Gui, D., Dorigo, O., Sullivan, P.
2012; 43 (8): 1339-1343
- **Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development** *MODERN PATHOLOGY*
Sullivan, P. S., Maresh, E. L., Seligson, D. B., Habeeb, O., Wadehra, M., Goodglick, L., Dorigo, O.
2012; 25 (8): 1140-1148
- **Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells** *NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE*
Sharma, S., Santiskulvong, C., Bentolila, L. A., Rao, J., Dorigo, O., Gimzewski, J. K.
2012; 8 (5): 757-766
- **Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease** *GYNECOLOGIC ONCOLOGY*
Karam, A., Dorigo, O.
2012; 125 (2): 346-351
- **Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy** *GYNECOLOGIC ONCOLOGY*
Penner, K. R., Dorigo, O., Aoyama, C., Ostrzega, N., Balzer, B. L., Rao, J., Walsh, C. S., Cass, I., Holschneider, C. H.
2012; 124 (3): 542-548
- **Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells** *ANTICANCER RESEARCH*
Fekete, M., Santiskulvong, C., Eng, C., Dorigo, O.
2012; 32 (2): 445-452
- **Personalizing CA125 Levels for Ovarian Cancer Screening** *CANCER PREVENTION RESEARCH*
Dorigo, O., Berek, J. S.
2011; 4 (9): 1356-1359
- **Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma** *CLINICAL CANCER RESEARCH*
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K. M., Karam, A., Mulholland, D., Eng, C., Wu, H., Song, M., Dorigo, O.
2011; 17 (8): 2373-2384
- **Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression** *CYTOSKELETON*
Karam, A. K., Santiskulvong, C., Fekete, M., Zabih, S., Eng, C., Dorigo, O.
2010; 67 (8): 535-544
- **Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector** *JOURNAL OF VIROLOGY*
Gallagher, S. D., Gil, J. S., Dorigo, O., Berk, A. J.
2009; 83 (7): 3249-3257
- **Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma**
Dorigo, O., Santiskulvong, C., Fekete, M., Karam, A., Mulholland, D., Eng, C., Wu, H.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2009: S9-S10
- **Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient** *AMERICAN JOURNAL OF TRANSPLANTATION*
Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., Dorigo, O., Rao, P. N., Pham, P. T., Pham, P. T.

2009; 9 (2): 428-432

- **HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review** *GYNECOLOGIC ONCOLOGY*
Karam, A., Berek, J. S., Stenson, A., Rao, J., Dorigo, O.
2008; 111 (3): 568-571
- **CA125: Megadaltos of novel opportunities** *GYNECOLOGIC ONCOLOGY*
Dorigo, O., Berek, J. S.
2007; 104 (3): 505-507
- **Enhanced expression of hypersensitive alpha 4*nAChR in adult mice increases the loss of midbrain dopaminergic neurons** *FASEB JOURNAL*
Schwarz, J., Schwarz, S. C., Dorigo, O., Stuetzer, A., Wegner, F., Labarca, C., Deshpande, P., Gil, J. S., Berk, A. J., Lester, H. A.
2006; 20 (7): 935-946
- **Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons** *The Journal of the Federation of American Societies for Experimental Biology*
Schwarz, J., Schwarz, S. C., Dorigo, O., Labarca, C., Deshpande, P., Gil, J., Berk, A., Lester, H. A.
2006: 935-946
- **Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells** *JOURNAL OF VIROLOGY*
Dorigo, O., Gil, J. S., Gallaher, S. D., Tan, B. T., Castro, M. G., Lowenstein, P. R., Calos, M. P., Berk, A. J.
2004; 78 (12): 6556-6566
- **Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons** *8th International Congress of Parkinsons Disease and Movement Disorders*
Schwarz, S. C., Dorigo, O., Labarca, C., Berk, A. J., Lester, H. A., Schwarz, J.
WILEY-LISS.2004: S42-S42
- **Specific keynote: Immunological therapy for ovarian cancer** *8th International Forum on Ovarian Cancer*
Berek, J. S., Dorigo, O., Schultes, B., Nicodemus, C.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2003: S105-S109
- **Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine** *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., MARCHESE, A., Ferre, F., Duffy, C., Carlo, D. J., Sherman, L. A., Gold, D. P., SOBOL, et al
2002; 129 (1): 99-106
- **A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Ghosh, K., Dorigo, O., Bristow, R., Berek, J.
2000; 191 (2): 212-215
- **IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile** *JOURNAL OF IMMUNOLOGY*
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., Parker, S. E.
1999; 163 (12): 6378-6385
- **Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model** *GYNECOLOGIC ONCOLOGY*
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., Fakhrai, H.
1998; 71 (2): 204-210
- **Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function** *JOURNAL OF NEUROSURGERY*
Dorigo, O., Turla, S. T., Lebedeva, S., Gjerset, R. A.
1998; 88 (3): 535-540
- **Gene therapy for ovarian cancer – Molecular scissors of the new millenium?** *Journal of Gynecologic Techniques*
Dorigo, O., Berek, J. S.
1998; 4: 149-162
- **Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model** *Gynecologic Oncology*

- Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., Fakhrai, H.
1998: 204-210
- **Progress and prospects in vaccine therapy for gynecologic cancers.** *Oncology (Williston Park, N.Y.)*
Gurski, K. J., Steller, M. A.
1997; 11 (11): 1727-?
 - **Construction and characterization of retroviral vectors for interleukin-2 gene therapy** *JOURNAL OF IMMUNOTHERAPY*
Fakhrai, H., Shawler, D. L., VANBEVEREN, C., Lin, H., Dorigo, O., Solomon, M. J., Gjerset, R. A., Smith, L., Bartholomew, R. M., Boggiano, C. A., Gold, D. P., SOBOL, R. E.
1997; 20 (6): 437-448
 - **Gene therapy for ovarian cancer: Development of novel treatment strategies** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*
Dorigo, O., Berek, J. S.
1997; 7 (1): 1-13
 - **Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma** *ONCOLOGY REPORTS*
Shawler, D. L., Dorigo, O., VANBEVEREN, C., Bartholomew, R. M., Fakhrai, H., SOBOL, R. E.
1997; 4 (1): 135-138
 - **Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma** *Oncology Reports*
Shawler, D. L., Dorigo, O., Van Beveren, C., Bartholomew, R. M., Fakhrai, H., Sobol, R. E.
1997; 4 (N1): 135-138
 - **Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., MERCOLA, D., Black, K. L., Royston, I., SOBOL, R. E.
1996; 93 (7): 2909-2914
 - **Immuno-gene therapy of colon carcinoma and central nervous tumors** *In: Gene Therapy and Cancer*
Sobol, R. E., Fakhrai, H., Shawler, D. L., Dorigo, O., Gjerset, R. A., Mercola, D., Koziol, J., Royston, I., Bartholomew, R.
1996
 - **COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA** *JOURNAL OF IMMUNOTHERAPY*
Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., SOBOL, R. E., Fakhrai, H.
1995; 17 (4): 201-208
 - **INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA** *GENE THERAPY*
SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., Carson, C., KHALEGHI, T., KOZIOL, J., Shifftan, T. A., Royston, I.
1995; 2 (2): 164-167
 - **CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY** *IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL*
Gjerset, R. A., Fakhrai, H., Shawler, D. L., Turla, S., Dorigo, O., GROVERBARDWICK, A., MERCOLA, D., Wen, S. F., Collins, H., Lin, H., Garcia, M. V., Kruse, C. A., Royston, et al
1995; 31 (3): 207-214
 - **INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY** *HUMAN GENE THERAPY*
SOBOL, R. E., Royston, I., Fakhrai, H., Shawler, D. L., Carson, C., Dorigo, O., GJERSET, R., Gold, D. P., KOZIOL, J., MERCOLA, D., VANBEVEREN, C., Wilson, D.
1995; 6 (2): 195-204
 - **Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies** *Vaccine Research*
Muller, S., Brams, P., Collins, H., Dorigo, O., Kohler, H.
1995; Vol 4 (No 4): 229-238
 - **VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER** *49th Meeting of the Deutschen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe*
Dorigo, O., Meier, W., Scheidel, P., Hepp, H.

SPRINGER HEIDELBERG.1993: 966–68

- **LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY** *49th Meeting of the Deutschen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe*
ROMISCH, M., Bauer, F., Daponte, A., Meier, W., Dorigo, O., Eiermann, W.
SPRINGER HEIDELBERG.1993: 1091–93
- **ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM** *2nd Symposium of the German-Heart-Institute - Coronary Endothelium and Smooth Muscle : Basic Aspects and Clinical Consequences*
Tillmanns, H., Neumann, F. J., Tiefenbacher, C., Dorigo, O., Parekh, N., Waas, W., Zimmermann, R., Steinhausen, M., Kuebler, W.
W B SAUNDERS CO LTD.1993: 82–86
- **A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS** *1ST INTERNATIONAL MEETING ON IMMUNOLOGICAL APPROACHES TO TUMOR THERAPY BY ANTIBODIES AND TUMOR CELL VACCINES*
Herndier, B., McGrath, M., Abbey, N., Wang, H. T., Ng, V., Dorigo, O., Kaplan, L., Muller, S., Kohler, H.
MARY ANN LIEBERT INC.1993: 529–37
- **A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS**
Muller, S., Collins, H., Brams, P., Wang, H., Dorigo, O., McGrath, M., Grant, M., Rosenthal, K., Kohler, H.
WILEY-BLACKWELL.1993: 68–68
- **NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING** *CORONARY ARTERY DISEASE*
Tillmanns, H., Neumann, F. J., Waas, W., Mall, G., Parekh, N., Tiefenbacher, C., Dorigo, O., Zimmermann, R., Dart, A. M., Steinhausen, M., Kubler, W.
1992; 3 (7): 586-592
- **SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME** *JOURNAL OF PERINATAL MEDICINE*
Gortner, L., Pohlandt, F., Bartmann, P., Terinde, R., Versmold, H., Dorigo, O.
1992; 20 (1): 25-28
- **PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA** *EUROPEAN HEART JOURNAL*
Tillmanns, H., Neumann, F. J., Parekh, N., Dorigo, O., Tiefenbacher, C., Zimmermann, R., Steinhausen, M., Kubler, W.
1990; 11: 10-15
- **MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART** *EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY*
Tillmanns, H., Neumann, F. J., Parekh, N., Zimmermann, R., Tiefenbacher, C., Dorigo, O., Steinhausen, M., Kubler, W.
1990; 39: S9-S12